Physician profile
Patrick Canan
NPI 1306845375
$1,746.57
in general payments reported to CMS, 2019-2025
22 companies · $79.42 in 2025
The $79.42 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $150 · 2023: $209 · 2024: $242 · 2025: $79.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.50 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $300.85 | 2019-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $236.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $179.95 | 2019 | |
| Pfizer INC. | $176.83 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $112.51 | 2019-2020 | |
| Glaxosmithkline, LLC. | $111.51 | 2019-2023 | Shingrix, Arexvy |
| Astellas Pharma US INC | $104.10 | 2024 | Veozah |
| Abbvie INC. | $100.02 | 2019-2020 | |
| Daiichi Sankyo INC. | $81.66 | 2019-2020 | |
| Lilly USA, LLC | $63.22 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $36.06 | 2019 | |
| Hikma Pharmaceuticals USA | $34.96 | 2019 | |
| Merck Sharp & Dohme LLC | $31.84 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $30.87 | 2019-2024 | Airsupra |
| Irhythm Technologies, INC. | $27.39 | 2023 | Zio Xt Patch |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.09 | 2019 | |
| Amarin Pharma, INC. | $18.00 | 2020 | |
| Abbott Laboratories | $17.75 | 2023 | Freestyle Libre 2 |
| Shire North American Group INC | $16.98 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.52 | 2019 | |
| Allergan, INC. | $13.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Canan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.